Sage Journals: Discover world-class research

Abstract

Introduction

Primary Sjögren’s syndrome (pSS) is a chronic inflammatory disease primarily affects exocrine glands dysfunction. Oxidative stress (OS) is a phenomenon occurring as a result of an imbalance between the generation of free radicals and antioxidant defense system. Hence, we aimed to establish the status of OS and inflammatory response according to the pSS disease activity index. In this context, we investigated malondialdehyde (MDA), and antioxidant enzymes during pSS. The possible association between MDA and nitric oxide (NO) levels and between MDA and some pro-inflammatory cytokines (IL-1β, IL-6, TNF-α, and IL-33).

Methods

The study has been conducted on 53 pSS patients. The antioxidant enzymes, represented by glutathione peroxidase (GSH-Px), catalase (CAT) and superoxide dismutase (SOD), were estimated by a colorimetric activity kit. Whereas, MDA value was assessed by measuring thiobarbituric acid reactive substances. Moreover, pro-inflammatory cytokines (IL-1β, IL-6, TNF-α, and IL-33) and NO were respectively quantified by enzyme-linked immunosorbent assays (ELISA) and the modified Griess.

Results

Interestingly, we report a notable reduction in our pSS patients’ antioxidant enzyme activity, while NO, MDA and proinflammatory cytokines values were significantly increased. pSS patients with higher disease activity had much stronger increases in NO and MDA levels. No significant difference was assessed in CRP level. Additionally, substantial significant correlations between plasmatic NO and MDA levels and between MDA, NO and IL-1β, IL-6, TNF-α cytokines were reported. However, no significant association was found between NO, MDA and IL-33 concentrations.

Conclusion

Collectively, our data showed altered oxidant-antioxidant balance in pSS patients. MDA, NO, IL-1β, IL-6, TNF-α seem to be good indicators in monitoring disease activity. Oxidative stress was closely related to inflammation in pSS. Exploiting this relationship might provide valuable indicators in the follow-up and prognosis of pSS with a potential therapeutic value.

Keywords

primary Sjögren’s syndrome oxidative stress inflammation proinflammatory cytokines nitric oxide

Introduction

Sjögren’s syndrome (SS) is a chronic systemic autoimmune condition, essentially defined by an inflammatory infiltration of the exocrine glands (primary SS [pSS]). This condition leads to xerostomia and xerophtalmia symptoms.^1,2 Other systemic connective tissue diseases may coexist with SS. In this situation, secondary SS (sSS) is then diagnosed.

The clinical spectrum of SS expands from sicca symptoms in the affected tissues such as eyes and mouth to extra-glandular systemic symptoms, which are associated with either immunocomplexes deposition (cutaneous vasculitis, hypocomplementemia, and peripheral neuropathy) or lymphoepithelial infiltrates in parenchymal organs. The most significant concern and the main factor impacting the mortality rate for SS patients is the development of B-cell non-Hodgkin lymphoma.^3,4

As many other complex disorders, SS seems to occur from a confluence of genetic and environmental factors along with aberrant autoimmune responses, leading to B and T cell hyperactivity, autoantibody production causing damages target organs.^5,6 In fact, SS is induced by intricate relationships between various immune cell types. In these conditions, cytokines are considered as essential components of this communication network. Abundant evidence now supports that cytokines imbalance contributes to immune dysfunction, triggers inflammation, and induce tissues damage during pSS.

Moreover, a number of strong lines of evidence highlight the involvement of a crucial interplay between changes induced by the immune-inflammatory responses and oxidative stress (OS). Chronic inflammation and disturbance in immune homeostasis might lead to more marked OS and more severe cell injury.⁷

Oxidative stress represents the imbalance between pro- and anti-oxidant systems, occurring with an increased secretion of reactive nitrogen which includes essentially nitric oxide (NO), and peroxynitrite (ONOO⁻); or oxygen species (ROS and RNS) or a decline in the ability of antioxidative defense system, leading to alteration in the function of different components and signaling pathways.

The relationship between oxidative injury, which is mainly characterized by malondialdehyde (MDA), and inflammation is tight because the stress could be originated by the inflammasome and the TLRs signaling.⁸ Growing evidence indicates that C-reactive protein (CRP) levels augment significantly in response to inflammation, injury and, infection, and exhibit elevated expression during inflammatory disease.⁹ Similarly, it has been reported that OS is elevated in patients with autoimmune disease, owing to overproduction of free radicals.^10,11 The antioxidant system includes antioxidant components like glutathione (GSH) and diverse antioxidant enzymes, like catalase (CAT), superoxide dismutase (SOD), peroxiredoxins (PRXs), and glutathione peroxidases (GSH-Px).^12,13 SOD constitutes an antioxidant enzyme converting superoxide anion (O₂⁻) into O₂ and H₂O₂. CAT and GSH-Px are also antioxidant enzymes, catalyzes the dismutation of H₂O₂. Myeloperoxidase (MPO) converts H₂O₂ into hypochlorous acid (HOCl), a potent cytotoxic oxidizing agent.¹⁴

In this context, less is known about the implication of OS in pSS. Studies of oxidative injury during pSS are limited. In this sense, the purpose of our study was to situate the status of OS characterized by MDA, and antioxidant enzymes in relation to the pSS disease activity index. In the same way, we performed correlation studies to assess the potential interconnection between OS markers, nitric oxide, and pro-inflammatory cytokines.

Patients and methods

Study subjects

The research involved 53 pSS patients (49 women and four men) with a mean age of 44.73 ± 12.17 years, recruited at the department of Internal Medicine of Issad Hassani and Douera hospitals and fulfilling the American-European consensus criteria for pSS, including histopathological criteria and also satisfying the 2016 American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR).^15,16 Briefly, inclusion criteria were: (i) a recent pSS diagnosis by the referring physician, MSG-biopsy samples with a focus score ≥1 and a treatment with low dose of oral steroids (5 mg/day). (i.e. when the patient fulfilled the classification criteria). Tear function was assessed from the results of Schirmer’s tests obtained from the physician records. All the patients recruited in our study have an abnormal Schirmer’s test (≤5 mm/5min). Based on laboratory indicators and organ involvement, EULAR Sjögren’s syndrome disease activity index (ESSDAI) was assessed in accordance with previously published criteria, in order to evaluate the pSS disease activity.^16,17 Patients with pSS were categorized as follows: low (ESSDAI <5), moderate (5 ≤ ESSDAI ≤13), and high disease activity (ESSDAI ≥14). The controls included 47 sex- and age-matched healthy controls (HC), including 44 women and three men, with a mean age of 42.40 ± 9.33. Subjects with symptoms of chronic or infectious diseases did not take part in this study. All patients were examined for extraglandular complications. The overall features of the study subjects are displayed in Table 1. Individuals, who have consumed antioxidant, as well as patients undergoing systemic treatment in the past 6 months and patients with sSS were excluded. All participants (patients and controls) enrolled here gave their written informed consent with signature. This study has been approved by our national ethics committee in accordance with the Helsinki Declaration.

Table 1.

Clinical and laboratory characteristics of patients with primary Sjögren’s according to the ESSDAI score.

Features	pSS patients
Features	Total (n = 53)	pSS-I (n = 23)	pSS-II (n = 19)	pSS-III (n = 11)
General
Gender: women/men	50/3	21/2	18/1	11/0
Age (years ± SD)	44.73 ± 12.17	42.69 ± 11.43	48.31 ± 13.73	42.81 ± 10.28
Age at diagnosis (years ± SD)	39.13 ± 10.47	40.04 ± 10.63	39.73 ± 10.3	36.18 ± 10.86
Disease duration (years ± SD)	5.67 ± 5.97	2.82 ± 2.87	8.57 ± 7.28	6.63 ± 6.02
Clinical
Articular involvement (%)	41.5	3.77	20.75	16.98
Liver involvement (%)	7.53	1.88	3.77	9.43
Lung involvement (%)	15.09	1.88	3.77	9.43
Renal involvement (%)	9.43	1.88	1.88	5.66
Neurological involvement (%)	20.74	1.88	7.54	11.32
Raynaud's phenomenon (%)	41.5	3.77	16.98	20.75
Vasculitis (%)	13.2	1.88	1.88	9.43
SG-enlargement (%)	20.75	0	3.77	19.98
Palpable Purpura (%)	7.54	1.88	0	5.66
Serological
Anti Ro (SSA) positive (%)	60.37	16.98	20.75	22.64
Anti La (SSB) positive (%)	30.18	1.88	9.43	18.86
Rhematoid factor (RF) positive (%)	22.64	1.88	11.32	9.43
Hypergammaglobulinemia (%)	47.15	7.54	18.86	20.75

Abbreviation: SD, standard deviation. (pSS-I:Low; pSS-II:moderate; and pSS-III: high disease activity); ESSDAI: EULAR Sjögren’s Syndrome Disease Activity Index.

Plasma analysis

CRP levels have been quantified using nephelometric assay, while, anti-SSA, anti-SSB and antinuclear (ANA) Abs have been performed according to a standard protocol.

Assessment of antioxidant enzymes

After an overnight fast, blood samples were aseptically taken in the morning and centrifuged for 10 minutes at 3000 r/min. Samples were than kept at −80°C until analysis. The levels of antioxidant enzymes were measured in accordance to the instructions of manufacturer. In a spectrophotometer, the absorbance was measured at 340 nm for serum glutathione peroxidase (MAK437-1 KT, Sigma-Aldrich, St Louis, MO, USA), at 540 nm for catalase (219,265-1KIT, Sigma-Aldrich, St Louis, MO, USA), and at 450 nm for superoxide dismutase (19,160-1KT-F, Sigma-Aldrich, St Louis, MO, USA).

Lipid peroxidation analysis

Lipid peroxidation was quantified using the determination of thiobarbituric acid reactive compounds (TBARS) in plasma.¹⁸ Following the MDA reaction with thiobarbituric acid, the absorbance at 532 nm was detected using a spectrophotometer.

Nitric oxide levels assessment

Plasma nitrites NO₂⁻ as an index of plasma NO concentrations, were evaluated by the modified Griess method as described previously.¹⁹ The absorbance was assessed in a spectrophotometer at 543 nm. The amounts of nitrites were calculated relative to standard curve.

Cytokines assay

Plasma IL-6, TNF-α, IL-1β, and IL-33 levels (sensitivity: 1.6, 1.7, one and 0.2 pg/mL, respectively) were assessed with commercial ELISA kit following the instructions provided by the manufacturer (Thermofisher scientific^®). The concentrations were evaluated relative to standard curves.

Statistical analysis

All results were reported as mean ± standard deviation (SD). Statistical analyses were performed using Graph-Pad PrismR software (GraphPad Inc., La Jolla, CA, USA). Statistical significance was evaluated by Student’s t-test for normal distribution and Mann–Whitney U test for abnormal distribution of unpaired variables. Correlations between variables were performed by Pearson’s correlation analysis for normally distributed data. Otherwise, Spearman’s rank correlation test was used. A p value ≤.05 was considered as statistically significant.

Results

Lipid peroxidation, CRP and nitric oxide analysis

As displayed in Figure 1, our data revealed that plasma NO and MDA in pSS patients were considerably higher when compared to HC (p < .0001 for both), in contrast to CRP levels, for which there was no significant increase.

Figure 1.

Plasma NO₂^-, MDA and CRP levels in healthy controls (HC, n = 47) and pSS patients (n = 53). Results are represented as mean ± SEM (p ≤ .0001; n.s: not significant).

Antioxidant enzyme assays

As reported in Figure 2. Our data indicated that SOD (EC 1.15.1.1), GSH-Px (EC 1.11.9) and CAT (EC 1.11.1.6) activities were significantly decreased in patients with pSS, when compared to HC (p < .001, p < .0001, and p < .001, respectively).

Figure 2.

CAT, SOD and GSH-Px activities from healthy controls (HC, n = 47) and pSS patients (n = 53). Results are expressed as mean ± SEM (p ≤ .01; p ≤ .0001).

Plasma cytokines levels

As seen in Figure 3, IL-1β, IL-6, TNF-α, and IL-33 plasma values were significantly elevated in pSS patients in comparison to HC (p < .0001, for all).

Figure 3.

IL1-β, IL-6, TNF-α and IL-33 plasmatic levels in healthy controls (HC, n = 47) and pSS patients (n = 53). Results are represented as mean ± SEM (p ≤ .0001, for all).

Cytokines and oxidative stress variables measurement according to the pSS disease activity state

Table 2 makes clear that individuals with higher disease activity had much stronger increases in NO and MDA levels. Furthermore, concerning proinflammatory cytokines, our findings demonstrated a significant difference in amounts of IL1β, TNF-α and IL-6, especially between pSS patients with low and high activity. However, disease activity does not appear to impact IL33 levels. Moreover, our results indicated that there was no discernible change in plasma levels of CRP regarding disease activity.

Table 2.

Cytokines and oxidative stress variables measurement according to the ESSDAI score.

Variables	pSS patients
	Total (n = 53)	pSS-I (n = 23)	pSS-II (n = 19)	pSS-III (n = 11)	Statistical significance
	Total (n = 53)	pSS-I (n = 23)	pSS-II (n = 19)	pSS-III (n = 11)	pSS-I vs pSSII	pSS-II vs pSSIII	pSS-I vs pSSIII
NO⁻₂ (mU/mL)	41.22 ± 14.33	31.6 ± 9.72	43.58 ± 12.47	57.29 ± 8.54	<0.01	<0.01	<0.01
MDA (mU/mL)	2.56 ± 0.71	2.15 ± 0.55	2.7 ± 0.62	3.17 ± 0.66	<0.01	0.05	<0.01
CAT (IU/mL)	20091.59 ± 2058.25	19608.81 ± 1554.72	20613.09 ± 2215.88	20200.28 ± 2609.1	n.s	n.s	n.s
SOD (U/mL)	64.17 ± 19.18	54.53 ± 19.94	71.26 ± 17.11	72.1 ± 11.51	n.s	n.s	n.s
GSH-Px (mU/mL)	59.72 ± 10.9	63.03 ± 6.59	55.19 ± 15.54	60.61 ± 4.72	n.s	n.s	n.s
CRP (mg/L)	3.72 ± 2.46	3.61 ± 2.43	3.61 ± 2.71	3.25 ± 1.4	n.s	n.s	n.s
IL-1β (pg/mL)	14.25 ± 3.61	13.21 ± 3.00	13.73 ± 2.63	17.33 ± 4.68	n.s	<0.001	<0.05
IL-6 (pg/mL)	28.44 ± 5.72	26.56 ± 5.09	28.57 ± 5.52	32.13 ± 5.91	n.s	n.s	<0.05
TNF-α (pg/mL)	13.36 ± 3.02	12.15 ± 2.55	12.93 ± 2.37	16.66 ± 2.7	n.s	n.s	<0.01
IL-33(pg/mL)	94.41 ± 14.9	95.49 ± 12.67	93.91 ± 14.39	93 ± 20.58	n.s	n.s	n.s

Abbreviation: SD, standard deviation. (pSS-I:Low; pSS-II:moderate; and pSS-III: high disease activity), ESSDAI: EULAR Sjögren’s Syndrome Disease Activity Index. p ≤ 0.05 values were accepted as statistically significant.

Correlation studies

Our data indicated, a potent positive correlation between NO and MDA concentrations among either pSS patients (r = 0.66, p < .0001. Figure 4(a)). However, a lack of significant association was notified between and MDA, NO and CRP concentrations (r = −0.15, p = .28; r = −0.09, p = .5, respectively. Figure 4(b)). Additionally, correlation studies between some markers of oxidative stress and pro-inflammatory cytokines were also carried out. Correlation investigations between TNF-α, IL-6, IL-1β, and MDA levels revealed a positive correlation (r = 0.46, p < .0001; r = 0.7, p < .0001; r = 0.55, p < .0001, respectively. Figure 5). Likewise, correlation analyses between TNF-α, IL-6, IL-1β, and NO concentrations revealed a similar pattern (r = 0.69, p < .0001; r = 0.59, p < .0001; r = 0.57, p < .0001, respectively. Figure 6). While, no significant associations were established between NO, MDA and IL-33 (r = 0.11, p = .4).

Figure 4.

(a) Correlation between NO₂^- and MDA levels. Plasma production of NO₂^- strongly correlated with MDA levels (r = 0.66, p < .0001). (b) Correlation between MDA, NO₂^- and CRP levels. A lack of significant correlation between plasma MDA, NO and CRP levels (r = −0.15, p = .28; r = −0.09, p = .5, respectively).

Figure 5.

Correlation between IL-6, IL1β, TNF-α, IL-33 and MDA levels. Plasma production of IL-6, IL1-β, TNF-α and IL-33 positively correlated with MDA levels (r = 0.70, p < .0001; r = 0.55, p < .0001; r = 0.46, p < .0001; r = 0.02, p = .21; respectively).

Figure 6.

Correlation between IL-6, IL1β, TNF-α, IL-33 and NO₂^- plasma levels. Plasma production of IL-6, IL1β, TNF-α and IL-33 positively correlated with NO₂^- levels (r = 0.59, p < .0001; r = 0.57, p < .0001; r = 0.69, p < .0001; r = 0.11, p = .4; respectively).

Moreover, we performed correlation between some oxidative stress variables, pro-inflammatory cytokines and ESSDAI score. A strong positive correlation was recorded between the NO, MDA levels and disease activity (r = 0.69, p < .0001; r = 0.54, p < .0001; respectively. Figure 7). Additionally, in regard to pro-inflammatory cytokines there was a significant positive correlation between IL-,1β, IL-6, TNF-α and the pSS disease activity (r = 0.29, p = .03; r = 0.49, p = .0002; r = 0.29, p = .03, respectively. Figure 8).

Figure 7.

Correlation between oxidative stress variables and the pSS disease activity index. Correlation between CAT, SOD and GSH-Px activities, NO₂^-, MDA levels and the pSS disease activity index. A significant positive correlation was shown between plasmatic production of NO₂^-, MDA and ESSDAI score (r = 0.69, p < .0001; r = 0.54, p < .0001, respectively).

Figure 8.

Correlation between proinflammatory cytokines and the PSS disease activity index. Correlation between IL-6, IL1β, TNF-α, IL-33 and the pSS disease activity. Plasma production of IL-6 IL-1β and TNF-α positively correlated with ESSDAI score (r = 0.29, p = .03 for both IL-6 and IL-1β; r = 0.49, p = .0002, respectively).

Discussion

Several factors having direct or indirect impact upon oxidant/antioxidant systems have been involved in pSS etiology.²⁰ Oxidative stress is considered as the off-balance of free radicals and antioxidants. At low or moderate concentrations, these molecules are essential for some biological processes such as intracellular cell signaling and homeostasis, induction of mitogenic response, immune defense against pathogens, and cell death.^21,22 In this context, accumulative literature evidence has shown that autoimmune phenomena characterizing pSS process results in an increase in OS. In turn, imbalance of oxidative stress exacerbates autoimmune diseases. It is acknowledged that infections, UV irradiation, ionizing radiation stress, smoking and others exogenous sources can induce and aggravate the pathobiology of autoimmune diseases.^13,9 These factors seem to have a tight relationship with oxidative stress. Indeed, ROS and RNS can be induced by environmental factors.²³

Despite the fact that NO is considered as a key signaling molecule in several physiological activities, however, like most other inflammatory mediators, excessive production of NO in response to inflammatory stimuli mediate cellular/tissue injury.^24–27 Importantly, NO is a crucial marker for oxidative stress and inflammation.²⁸ Our report revealed a high rise in NO levels, which can result in the production of peroxynitrite. This last potent oxidant molecule induces oxidative cell injury by altering DNA, protein, and lipids, and in turn amplify the pathologic processes of diseases, leading to proinflammatory, deleterious and destructive effects.^29–31 Indeed, reaction between O₂^- and NO forms H₂O₂ which is far more deleterious and reactive than its precursors and it is able to oxidize and nitrate nucleotides, proteins, and lipids.^32,33 Interestingly, a similar pattern of increase was observed for MDA production was observed in our study. In the same line, prior research concluded that lipid peroxides play a role in the etiology of a number of autoimmune disorders and allows us to support the role of OS during pSS.^34,35 Increased levels of MDA indicate an important generation of ROS.³⁶ Free radicals are byproducts of normal cellular metabolism. However, if they are not properly scavenged, these reactive species may initiate lipid peroxidation, which may damage cell structure and function.^37,38 MDA has been extensively considered in LPO studies and suggested as a biomarker of lipid peroxidation.³⁹ In this context, increased MDA concentrations have been linked with divers clinical characteristics and tissue damage during systemic lupus erythematosus.^40,41

Under physiological conditions, the endogenous ROS can be scavenged by enzymatic antioxidants like: SOD, glutathione peroxidase and CAT.⁴² However, under some pathological situations, the dynamic balance between the production and degradation of ROS may be defective and consequently could leads to a marked augmentation in the levels of ROS.⁴² Hence, we also aimed to measure activities of antioxidant enzymes. In this context, we report a strong reduction in the enzymes activities of CAT, GSH-Px, and SOD during pSS. Meanwhile, lowered activity of antioxidant enzymes could explain the increase of MDA level described in our report. The depletion of the antioxidant defense system following the strong formation of free radicals may provide an explanation for the decline in antioxidant enzymes. Indeed, the antioxidant system is not able to efficiently detoxify free radicals, leading consequently to OS status.

Enzymatic antioxidants preserve the oxide/reduction in cell equilibrium. This is why, antioxidant system should maintain the balance of redox status. Anti-oxidant enzymes have been intensively studied during autoimmunity but the results were controversies. Our result agrees with previous works supporting a significant diminution in SOD activity in patients with autoimmune diseases.^43,44 Reduction in SOD activity is probably attributable to the SOD antibodies which cause lead to the production of immune complexes production.⁴⁵

In the current study, low amounts of GSH-Px and catalase activities were also detected. The major peroxisomal antioxidant responsible for catalyzing the conversion of H₂O₂ into O₂ and H₂O is catalase, without free radicals production.⁴⁶ Whereas, Glutathione peroxidase is considered as an intracellular antioxidant enzyme which reduces H₂O₂ to H₂O in the presence of reduced glutathione as a hydrogen donor. Glutatione peroxidase plays a pivotal role during lipid peroxidation damage.⁴⁷ Intriguingly, the reduced activities of CAT and GSH-Px could be caused to the inactivation of the enzymes by hydrogen peroxide.⁴⁸

In our current study, CRP levels did not show any significant association with outcome in our category of patients. Our findings are consistent with a prior research reporting that pSS is characterized by a relatively low CRP response.⁴⁹

Hence, we report that plasma of TNF-α, IL-1β, IL-6, and IL-33 increased markedly in pSS patients relative to controls. This finding provides additional support to the notion that inflammatory mediators are crucial for the pathophysiology of SS. In fact, there are several compelling lines of evidence delineating the destructive function of inflammation in pSS^50,51 Next, we investigated whether proinflammatory cytokines and OS factors varied based on the stage of pSS disease activity. Remarkably, our data revealed that the increases of NO and MDA levels were significantly greater in pSS patients with higher disease activity. When we combine our two observations concerning high concentrations of NO and MDA described here and the decrease in antioxidant enzymes, we can suggest the existence of a compromised antioxidant balance, which may result in elevated ROS levels or decreased antioxidant levels, ultimately leading to a state of oxidative stress. Indeed, In fact, OS originates when the antioxidant defense is surpassed by the production of ROS. In a comparable manner, it has already been shown that increased OS is correlated with the activity of autoimmune diseases.^52,53

Furthermore, we observed a noteworthy elevation in the amounts of IL1β, IL-6, and TNF-α, particularly among patients with pSS expressing mild and high activity disease. Greater response in samples with more active pSS conditions implies that these markers might be helpful in assessing how the disease is progressing as well as clarifying the pathophysiological causes. However, CRP levels̍ does not seem very useful in assessing the disease progression in this condition.

Therefore, and consistent with our present result revealing the eminent importance of NO, MDA related oxidative stress, and proinflammatory cytokines in SS, we then, sought to evaluate the relationship between serum oxidative stress marker and inflammation in SS by performing correlation study. As far as we know, no earlier report had examined the relationship between proinflammatory cytokines, and oxidative stress during pSS. In this way, our data indicated a highly positive association between plasma NO and MDA measurements during pSS. To our knowledge, this is the first reporting an interconnection between NO and MDA measurements during pSS, suggesting that the NO status is associated with lipid peroxidation in this condition. Accumulative literature evidence has supported that oxidative stress induces oxidation of lipids. In this context, it has been postulated that interaction of ROS with lipids, especially the hydroxyl radical, reacts with lipid membranes and leads to MDA production.^41,54

Here, we also reported a lack of correlation between MDA, CRP and MDA. This data could be related to the fact that levels of CRP have been found within normal limits in our category of patients. In the same line, no correlation between CRP and MDA was also described in previous works.^55,56

Remarkably, our result revealed a positive significant correlation between NO, MDA and the proinflammatory cytokines (IL1β, IL-6 and TNF-α), supporting consequently a crucial relationship between enhanced OS, inflammation and pSS disease and that both OS and inflammation are intimately related in pSS. This observation has not been established for IL-33. Subsequently, IL1β, IL-6 and TNF-α, are considered as potent inflammatory cytokines and consequently may have a crucial role and higher association with OS, contrary to IL-33. In the same way, it has been previously reported free radical generation has been shown to be triggered by a rise in inflammatory mediators and likewise, excessive ROS production may trigger pro-inflammatory signaling pathways and activate the release of numerous inflammatory mediators, including IL-1β and TNFα, via several different mechanisms.⁵⁷ Indeed, disproportionate OS could play a significant function during the inflammatory response of gene expression promoting inflammation, notably via activation of the nuclear transcription factor NF-kβ and activator protein-1 which in turn up-regulates proinflammatory cytokines.⁴¹ When summarizing the results of some studies, a strong correlation has been established between OS and inflammation in a number of diseases, including type 2 diabetes and irritable bowel syndrome.^58,59

In our report, the highest correlations were noted between IL-6 and MDA, and between TNF-α and NO. According to this result, these potent proinflammatory cytokines appears to be associated more closely to OS than other cytokines. This positive correlation between oxidative stress marker and these proinflammatory cytokines suggests that reducing inflammation and OS could alleviate pSS disease severity. Moreover, According to some research, excessive OS may contribute significantly to the pathophysiology of autoimmune diseases by increasing inflammation.⁶⁰ Inflammatory processes have been shown to reduce cellular antioxidant capacity and induce oxidative stress.⁶¹ Both OS and inflammation processes feed off each other, creating a vicious cycle that can sustain perpetuate the inflammatory response.⁶²

Moreover, to assess if a link between some markers of OS, proinflammatory cytokines and pSS exists, we examined their relationship with pSS disease activity index. Interestingly, a positive significant correlation between NO, MDA, the proinflammatory cytokines (IL-6, TNF-α, and IL-1β) and pSS disease activity was revealed. These markers seem usefulness for monitoring pSS disease evolution. Nevertheless, the amount of IL-33 does not seem to have an effect on the disease’s activity.

However, it is important to take into account some limitations of our work when evaluating the findings. Firstly, our study was performed without sample size calculation. Large-scale study is required to validate these results. The second limitation of this study concerns the failure to predict the responses of patients using different therapeutic compounds.

Conclusion

The outcome of our study increasingly supports a potential interaction between inflammation and OS in pSS disease. Indeed, MDA, proinflammatory cytokines, and NO showed significant association, supporting consequently a crucial interconnection between inflammation and OS process during pSS. Therefore, we propose to focus on the impact of antioxidants administration, which may be beneficial against disease-related increases in oxidative stress and may positively affect the clinical damage induced by oxidative stress, since it has been established that oxidative stress was clearly implicated in the pathogenesis of pSS.

Footnotes

Acknowledgments

All of the study participants are acknowledged and thanked by the authors.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was partially funded by the Algerian Thematic Agency for Research in Health Sciences (ATRSS). Code number: 04/06/01/14/080.

Ethical statement

ORCID iDs

Sarah Benchabane

Zohra Hadjimi

References

Fox

(2005) Sjögren’s syndrome. Lancet 366: 321–331. DOI: 10.1016/S0140-6736(05)66990-5.

Negrini

Emmi

Greco

, et al. (2022) Sjögren’s syndrome: a systemic autoimmune disease. Clinical and Experimental Medicine 22: 9–25. DOI: 10.1007/s10238-021-00728-6.

Routsias

Goules

Charalampakis

, et al. (2013) Malignant lymphoma in primary Sjögren’s syndrome: an update on the pathogenesis and treatment. Semin Arthritis Rheum 43: 178–186. DOI: 10.1016/j.semarthrit.2013.04.004.

Ioannidis

Vassiliou

Moutsopoulos

(2002) Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren’s syndrome. Arthritis Rheum 46: 741–747. DOI: 10.1002/art.10221.

Delaleu

Jonsson

Appel

, et al. (2008) New concepts in the pathogenesis of Sjögren’s syndrome. Rheumatic Diseases Clinics of North America 34: 833–845. DOI: 10.1016/j.rdc.2008.08.004.

Parisis

Chivasso

Perret

, et al. (2020) Current state of knowledge on primary Sjögren’s syndrome, an autoimmune exocrinopathy. Journal of Clinical Medicine 9(7): 2299. DOI: 10.3390/jcm9072299.

Mukhopadhyay

Eid

Abdelmegeed

, et al. (2018) Interplay of oxidative stress, inflammation, and autophagy: their role in tissue injury of the heart, liver, and kidney. Oxidative Medicine and Cellular Longevity 2018: 2090813. DOI: 10.1155/2018/2090813.

Sharma

Tate

Mathew

, et al. (2018) Oxidative stress and NLRP3-inflammasome activity as significant drivers of diabetic cardiovascular complications: therapeutic implications. Frontiers in Physiology 9: 114. DOI: 10.3389/fphys.2018.00114.

Luan

Yao

(2018) The clinical significance and potential role of C-reactive protein in chronic inflammatory and neurodegenerative diseases. Frontiers in Immunology 9: 1302. DOI: 10.3389/fimmu.2018.01302.

10.

Smallwood

Nissim

Knight

, et al. (2018) Oxidative stress in autoimmune rheumatic diseases. Free Radical Biology and Medicine 125: 3–14. DOI: 10.1016/j.freeradbiomed.2018.05.086.

11.

Vona

Pallotta

Cappelletti

, et al. (2021) The impact of oxidative stress in human pathology: focus on gastrointestinal disorders. Antioxidants 10: 201. DOI: 10.3390/antiox10020201.

12.

Dietz

(2003) Plant peroxiredoxins. Annual Review of Plant Biology 54: 93–107. DOI: 10.1146/annurev.arplant.54.031902.134934.

13.

Navrot

Collin

Gualberto

, et al. (2006) Plant glutathione peroxidases are functional peroxiredoxins distributed in several subcellular compartments and regulated during biotic and abiotic stresses. Plant Physiology 142: 1364–1379. DOI: 10.1104/pp.106.089458.

14.

Weydert

Cullen

(2010) Measurement of superoxide dismutase, catalase and glutathione peroxidase in cultured cells and tissue. Nat Protoc 5(1): 51–66. DOI: 10.1038/nprot.2009.197.

15.

Vitali

Bombardieri

Jonsson

, et al. (2002) Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American–European Consensus Group. Annals of the Rheumatic Diseases 61: 554–558.

16.

Shiboski

Seror

, et al. (2017) American College of Rheumatology/European League against rheumatism classification criteria for primary Sjögren's syndrome: a consensus and data-driven methodology involving three international patient cohorts. Arthritis and Rheumatology 69(1): 35–45. DOI: 10.1002/art.39859.

17.

Seror

Bowman

Brito-Zeron

,et al. (2015) EULAR Sjögren’s syndrome disease activity index (ESSDAI): a user guide. RMD Open 20(1):e000022. DOI: 10.1136/rmdopen-2014-000022.

18.

Nourooz-Zadeh

Tajaddini-Sarmadi

Ling

, et al. (1996) Low-density lipoprotein is the major carrier of lipid hydroperoxides in plasma. Relevance to determination of total plasma lipid hydroperoxide concentrations. Biochemical Journal 313: 781–786. DOI: 10.1042/bj3130781.

19.

Touil-Boukoffa

Bauvois

Sanceau

, et al. (1998) Production of nitric oxide (NO) in human hydatidosis: relationship between nitrite production and interferon gamma levels. Biochimie 80: 739–744. DOI: 10.1016/s0300-9084(99)80027-3.

20.

Yilmaz

Gemcioglu

Baser

, et al. (2021) Thiol/disulfide homeostasis impaired in patients with primary Sjögren's syndrome. Journal of Medical Biochemistry 5(3):270–276. DOI: 10.5937/jomb0-27281

21.

Dröge

(2002) Free radicals in the physiological control of cell function. Physiological Reviews 82(1): 47–95. DOI: 10.1152/physrev.00018.2001.

22.

Valko

Leibfritz

Moncol

, et al. (2007) Free radicals and antioxidants in normal physiological functions and human disease. The International Journal of Biochemistry and Cell Biology 39(1): 44–84. DOI: 10.1016/j.biocel.2006.07.001.

23.

Aranda-Rivera

Cruz-Gregorio

Arancibia-Hernández

, et al. (2022) RONS and oxidative stress: an overview of basic concepts. Oxygen 2: 437–478. DOI: 10.3390/oxygen2040030.

24.

Lappin

Kjeldsen

Sander

, et al. (2000) Inducible NO synthase expression in periodontitis. Journal of Periodontal Research 35: 369–373. DOI: 10.1034/j.1600-0765.2000.035006369.x.

25.

Hadjimi

Belguendouz

Benchabane

, et al. (2023) Increased salivary cytokines and nitric oxide levels in behçet's disease: interleukin-32, a novel player in disease prognosis. Endocrine, Metabolic and Immune Disorders - Drug Targets 23(3): 347–355. DOI: 10.2174/1871530322666220512120948.

26.

Ghozali

Belguendouz

Messaoudene

, et al. (2021) In-vitro immunomodulatory effects of nicotine on Nitric Oxide, interleukin 1β and interleukin 37 production in human peripheral blood mononuclear cells (PBMC) from patients with Behçet disease. Int Immunopharmacol 101(Pt A): 108189. DOI: 10.1016/j.intimp.2021.108189.

27.

Benchabane

Slimani-Kaddouri

Acheli

, et al. (2022) Association between increased bcl-2, fas and FasL levels and inflammation extent in labial salivary glands during primary Sjögren's syndrome. Endocr Metab Immune Disord Drug Targets 22(3): 328–338. DOI: 10.2174/1871530321666210809155147.

28.

Rajeshwar

Kaul

Al-Hazzani

, et al. (2011) C-reactive protein and nitric oxide levels in ischemic stroke and its subtypes: correlation with clinical outcome. Inflammation 35: 978–984. DOI: 10.1007/s10753-011-9401-x.

29.

McCord

(2000) The evolution of free radicals and oxidative stress. American Journal of Medicine 108(8): 652–659. DOI: 10.1016/s0002-9343(00)00412-5.

30.

Polat

Taysi

Gul

, et al. (2002) Oxidant/antioxidant status in blood of patients with malignant breast tumour and benign breast disease. Cell Biochemistry and Function 20: 327–331. DOI: 10.1002/cbf.980.

31.

Birben

Sahiner

Sackesen

, et al. (2012) Oxidative stress and antioxidant defense. The World Allergy Organization Journal 5(1): 9–19. DOI: 10.1097/WOX.0b013e3182439613.

32.

Salgo

Pryor

(1996) Trolox inhibits peroxynitrite-mediated oxidative stress and apoptosis in rat thymocytes. Archives of Biochemistry and Biophysics 333(2): 482–488. DOI: 10.1006/abbi.1996.0418.

33.

Pacher

Beckman

Liaudet

(2007) NO and peroxynitrite in health and disease. Physiological Reviews 87: 315–424. DOI: 10.1152/physrev.00029.2006.

34.

Devasagayam

Tilak

Boloor

, et al. (2004) Free radicals and antioxidants in human health: current status and future prospects. The Journal of the Association of Physicians of India 52: 794–804. DOI: 10.4103/0973-7847.70902.

35.

Lobo

Patil

Phatak

, et al. (2010) Free radicals, antioxidants and functional foods: impact on human health. Pharmacognosy Reviews 4(8): 118–126. DOI: 10.4103/0973-7847.70902.

36.

Nita

Grzybowski

(2016) The role of the reactive oxygen species and oxidative stress in the pathomechanism of the age-related ocular diseases and other pathologies of the anterior and posterior eye segments in adults. Oxidative Medicine and Cellular Longevity 2016: 3164734. DOI: 10.1155/2016/3164734.

37.

Taysi

Kocer

Memisogullari

, et al. (2002) Serum oxidant/antioxidant status in patients with Behçet's disease. Annals of Clinical and Laboratory Science 32(4): 377–382.

38.

Zhang

Gomez

, et al. (2019) Reactive oxygen species-induced lipid peroxidation in apoptosis, autophagy, and ferroptosis. Oxid Med Cell Longev 13: 5080843. DOI: 10.1155/2019/5080843.

39.

Shibamoto

(2006) Analytical methods for trace levels of reactive carbonyl compounds formed in lipid peroxidation systems. Journal of Pharmaceutical and Biomedical Analysis 41: 12–25. DOI: 10.1016/j.jpba.2006.01.047.

40.

Hassan

Gheita

Kenawy

, et al. (2011) Oxidative stress in systemic lupus erythematosus and rheumatoid arthritis patients: relationship to disease manifestations and activity. International Journal of Rheumatic Diseases 14(4): 325–331. DOI: 10.1111/j.1756-185X.2011.01630.

41.

Shah

Mahajan

Sah

et al. (2014) Oxidative stress and its biomarkers in systemic lupus erythematosus. Journal of Biomedical Science 21: 23. DOI:10.1186/1423-0127-21-23.

42.

Wei

Chen

Hou

, et al. (2000) Nitric oxide induces oxidative stress and apoptosis in neuronal cells. Biochimica et Biophysica Acta 1498(1): 72–79. DOI:10.1016/s0167-4889(00)00078-1.

43.

Kurien

Scofield

(2006) Lipid peroxidation in systemic lupus erythematosus. Indian Journal of Experimental Biology 44(5): 349–356.

44.

Mateen

Moin

Khan

, et al. (2016) Increased reactive oxygen species formation and oxidative stress in rheumatoid arthritis. PLoS ONE 11(4): 0152925. DOI: 10.1371/journal.pone.0152925.

45.

Kurien

Scofield

(2003) Free radical mediated peroxidative damage in systemic lupus erythematosus. Life sciences 73: 1655–1666. DOI: 10.1016/s0024-3205(03)00475-2.

46.

Nandi

Yan

Jana

, et al. (2019) Role of catalase in oxidative stress- and age-associated degenerative diseases. Oxidative Medicine and Cellular Longevity 11: 9613090. DOI: 10.1155/2019/9613090.

47.

Sen

(2000) Cellular thiols and redox-regulated signal transduction. Current Topics in Cellular Regulation 36: 1–30. DOI: 10.1016/s0070-2137(01)80001-7.

48.

D’souza

Kurien

Rodgers

, et al. (2008) Detection of catalase as a major protein target of the lipid peroxidation product 4-HNE and the lack of its genetic association as a risk factor in SLE. BMC Medical Genomics 9: 62. DOI: 10.1186/1471-2350-9-62.

49.

Moutsopoulos

Elkon

Mavridis

, et al. (1983) Serum C-reactive protein in primary Sjögren's syndrome. Clinical and Experimental Rheumatology 1(1): 57–58.

50.

Youinou

Pers

(2011) Disturbance of cytokine networks in Sjögren’s syndrome. Arthritis Research and Therapy 13: 227. DOI: 10.1186/ar3348.

51.

Benchabane

Boudjelida

Toumi

, et al. (2016) A case for IL-6, IL-17A, and nitric oxide in the pathophysiology of Sjogren’s syndrome. International Journal of Immunopathology and Pharmacology 29(3): 386–397. DOI: 10.1177/0394632016651273.

52.

Wojcik

Gegotek

Zarkovic

, et al. (2021) Oxidative stress and lipid mediators modulate immune cell functions in autoimmune diseases. International Journal of Molecular Sciences 22(2): 723. DOI: 10.3390/ijms22020723.

53.

Duarte-Delgado

Cala

Barreto

, et al. (2022) Metabolites and metabolic pathways associated with rheumatoid arthritis and systemic lupus erythematosus. Journal of Translational Autoimmunity 5: 100150. DOI: 10.1016/j.jtauto.2022.100150.

54.

Cherian

Peter

Narayanan

, et al. (2019) Malondialdehyde as a marker of oxidative stress in periodontitis patients. Journal of Pharmacy and Bioallied Sciences 11(2): S297–S300. DOI: 10.4103/JPBS.JPBS_17_19.

55.

Bircan

Sütçü

Gökırmak

(2008) Total antioxidant capacity and C-reactive protein levels in patients with community-acquired pneumonia. Turkish Journal of Medical Sciences 38: 537–544.

56.

Atik

Putri Pratiwi

Hamijoyo

(2020) Correlation between C-reactive protein with malondialdehyde in systemic lupus erythematosus patients. International Journal of Rheumatology 1: 8078412. DOI: 10.1155/2020/8078412.

57.

Mittal

Siddiqui

Tran

, et al. (2014) Reactive oxygen species in inflammation and tissue injury. Antioxidants and Redox Signaling 20(7): 1126–1167. DOI: 10.1089/ars.2012.5149.

58.

Oguntibeju

(2019) Type 2 diabetes mellitus, oxidative stress and inflammation: examining the links. International Journal of Physiology, Pathophysiology and Pharmacology 11(3): 45–63.

59.

Choghakhori

Abbasnezhad

Hasanvand

, et al. (2017) Inflammatory cytokines and oxidative stress biomarkers in irritable bowel syndrome: association with digestive symptoms and quality of life. Cytokine 93: 34–43. DOI: 10.1016/j.cyto.2017.05.005.

60.

Yan

Chen

Xia

(2023) Oxidative stress contributes to inflammatory and cellular damage in systemic lupus erythematosus: cellular markers and molecular mechanism. Journal of Inflammation Research 4(16): 453–465. DOI: 10.2147/JIR.S399284.

61.

Khansari

Shakiba

Mahmoudi

(2009) Chronic inflammation and oxidative stress as a major cause of age-related diseases and cancer. Recent Patents on Inflammation and Allergy Drug Discovery 3(1): 73–80. DOI: 10.2174/187221309787158371.

62.

Wakamatsu

Dogru

Matsumoto

, et al. (2013) Evaluation of lipid oxidative stress status in Sjögren syndrome patients. Investigative Ophthalmology And Visual Science 7;54(1):201–210. DOI: 10.1167/iovs.12-10325.

Exploring the relationship between oxidative stress status and inflammatory markers during primary Sjögren’s syndrome: A new approach for patient monitoring

Abstract

Introduction

Methods

Results

Conclusion

Keywords

Introduction

Patients and methods

Study subjects

Plasma analysis

Assessment of antioxidant enzymes

Lipid peroxidation analysis

Nitric oxide levels assessment

Cytokines assay

Statistical analysis

Results

Lipid peroxidation, CRP and nitric oxide analysis

Antioxidant enzyme assays

Plasma cytokines levels

Cytokines and oxidative stress variables measurement according to the pSS disease activity state

Correlation studies

Discussion

Conclusion

Footnotes

Acknowledgments

Declaration of conflicting interests

Funding

Ethical statement

ORCID iDs

References